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Objective: Polycystic ovary syndrome (PCOS) is associated with altered lipid profile and 
increased small, dense LDL particles (sdLDL). Considering that paraoxonase 1 (PON1) is an 
anti-oxidative enzyme located on high-density lipoprotein (HDL) particles, the aim of this 
study was to investigate the connection between oxidative stress (OS) and PON1 activity 
with lipoprotein subclasses in PCOS depending on obesity. Methods: In 115 PCOS patients 
lipoprotein subclasses distributions were determined by gradient gel electrophoresis. OS 
status was assessed by total oxidative status (TOS), advanced oxidation protein products 
(AOPP), malondialdehyde (MDA), prooxidant-antioxidant balance (PAB), total antioxidant 
status (TAS) and superoxide dismutase (SOD) and PON1 activity. Results: Overweight/obese 
PCOS patients (n=55) had increased OS compared to normal weight patients (n=60). In 
addition, overweight/obese group had lower HDL size and higher proportion of HDL 3a 
subclasses (P<0.05). PAB was in negative correlation with HDL 2a (P<0.001), whereas 
MDA and SOD correlated positively with HDL 3 subclasses (P<0.05). Serum PON1 activity 
was positively associated with proportions of PON1 activity on HDL 2b (P<0.05) and 2a 
(P<0.01), but negatively with the proportion on HDL 3 particles (P<0.01). LDL B phenotype 
patients had increased TAS, SOD and PON1 activity on HDL 2b, but decreased PON1 
activity on HDL 3 subclasses. Conclusion: OS is associated with altered lipoprotein 
subclasses distribution in PCOS patients. Obesity in PCOS affects the profile of HDL 
subclasses, reflected through the reduced proportion of PON1 activity on HDL 3 subclasses 
in the presence of sdLDL particles. 
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Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women in the 
reproductive period [1]. Because of its heterogeneity, elusiveness regarding etiology and 
diagnostic difficulties, PCOS is a complex endocrine and metabolic condition. The key risk 
factors which affect cardiovascular disease (CVD) risk in PCOS with complex mechanisms 
are dyslipidemia, increased oxidative stress (OS) [2] and chronic low-grade inflammation [3]. 
Recent studies have shown that women with PCOS, especially obese patients, have a 
significantly altered lipid profile characterized by qualitative changes of low-density 
lipoproteins (LDL), in terms of increased small, dense LDL particles (sdLDL), 
hypertriglyceridemia and reduced HDL-C concentrations [4]. This so-called “atherogenic 
lipoprotein phenotype” (ALP) represents a form of dyslipidemia that contributes to greater 
CVD risk [5]. Namely, sdLDL comprises LDL particles smaller than 25.5 nm, which are 
considered as the most atherogenic LDL subfractions. In addition, increased levels of 
oxidized LDL (oxLDL) were confirmed in women with PCOS, suggesting that lipid 
metabolism in PCOS is associated with OS [6].  
OS is defined as an imbalance between excessive formation of reactive oxygen 
species (ROS) and reduced antioxidant defence capacity. The pathophysiological mechanism 
of OS contribution in PCOS development remains vague, but numerous studies have found 
that PCOS is associated with OS [7]
 
[8]. We recently assessed OS biomarkers and proposed 
the evaluation of OXY-score as a comprehensive measure of OS status in women with PCOS 
[9].  
High-density lipoprotein (HDL) constitutes a heterogeneous group of particles [10] 
and previous studies suggested a relationship between altered HDL subclasses distribution 
and CVD risk [11]. Current research of anti-atherogenic roles of HDL particles is focused on 
evaluation of their functionality in addition to HDL subclasses distribution. However, data on 
HDL particles distribution and functionallity in PCOS are scarse.  
The antioxidative/anti-inflammatory role of HDL particles depends on the presence of 
antioxidant enzymes. Paraoxonase 1 (PON1) is a circulating esterase and lactonase associated 
with apolipoprotein A1 on HDL particles [12]. Antioxidant activity of PON1 is achieved by 




[14]. OS contributes to reducing 
PON1 activity by changing the redox status of free sulfhydryl groups of the protein molecule 
of this enzyme [15].  It is also clearly established that PON1 preferentially associates with 
small HDL 3 particles and then shifts to larger HDL 2 subclasses during the course of HDL 
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conditions may affect HDL maturation and, consequently, the distribution of PON1 between 
HDL 2 and HDL 3 particles [17].  
Taking all these facts together, we hypothesized that dyslipidemia, oxidative stress, and 
inflammation could be releated with pro-atherogenic changes in lipoprotein subclasses 
profiles in women with PCOS. Therefore, the aim of this study was to analyze the association 
of OS status with HDL and LDL particle size and subclasses, as well as with PON1 activity 
distribution on HDL subclasses in women with PCOS, especially regarding their obesity 
status.  
 
Material and methods 
Subjects and ethics 
In total, 115 PCOS patients, 60 normal weight women (mean BMI: 21.24 ± 1.98 kg/m
2
) and 
55 overweight or obese women (mean BMI: 32.26 ± 5.4 kg/m
2
), aged between 29 and 39 
years, were included in this study. The patients were recruited at the Clinic of Endocrinology, 
Diabetes and Metabolic Diseases, Clinical Centre of Serbia, Belgrade. PCOS was defined 
based on the revised Rotterdam Consensus Criteria (2003) [18]. All patients were recruited 
during the early follicular phase of the menstrual cycle, or at any time if they had severe 
oligomenorrhea or amenorrhea.  
Written informed consent was voluntary obtained from all subjects. The whole study was 
planned and conducted respecting the principles of the Declaration of Helsinki (Edinburgh, 
2000). The study protocol was evaluated and approved by Ethics Committees of the Faculty 
of Medicine and Faculty of Pharmacy, University of Belgrade. 
Anthropometric measurements 
Measurements of body weight and height, waist and hip circumferences (WC and HC) were 
carried out in the morning in a fasting state and BMI and waist-to-hip ratio (WHR) were 
calculated. 
 
Biochemical analyses  
Blood samples were collected in the morning after a 12 h fasting period in the follicular phase 
of the cycle (on the 2nd or the 3rd day). Plasma and serum were separated and stored until 
analyses. 
Fasting serum glucose, total cholesterol (TC), HDL-C, triglycerides (TG) and C-
reactive protein (CRP) concentrations were determined using commercially available 
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Germany) analyser. The concentration of LDL-C was calculated by the Friedewald formula 
[19]. 
Total oxidative status (TOS), advanced oxidation protein products (AOPPs), 
malondialdehyde (MDA), prooxidant-antioxidant balance (PAB), total antioxidative status 
(TAS), superoxide dismutase (SOD) and paraoxonase 1 (PON1) were measured on ILab 300
+
 
(Instrumentation Laboratory, Milan, Italy). For redox status parameters, the intra-assay and 
inter-assay coefficients of variance for all assays were below 4.3% and 8.2%, respectively.  
Plasma HDL and LDL particles were separated using a non-denaturing 3-31% 
polyacrylamide gradient gel electrophoresis method [20]. The HDL and LDL particle size 
determination and subclasses analyses were described in detail and published elsewhere [21]. 
In brief, the sizes of LDL and HDL particles were determined based on migration distance of 
the major peaks in densitometric profile, from calibration curve made from high molecular 
weight protein standards, carboxylated polystyrene microsphere beads and human plasma 
with two LDL subclasses of known diameters. Relative proportions of LDL and HDL 
subclasses were determined by analysing areas under the peaks that correspond to the known 
ranges of particle diameters: LDL I (27.2-28.5 nm), LDL II (25.5-27.2 nm), LDL III (24.2-
25.5 nm), LDL IV (22.0-24.2 nm), HDL 2b (9.7-12.0 nm), HDL 2a (8.8-9.7 nm), HDL 3a 
(8.2-8.8 nm), HDL 3b (7.8-8.2 nm) and HDL 3c (7.2-7.8 nm). Based on LDL size, the 
patients were further classified as the carriers of LDL phenotype A (LDL diameter >25.5 nm) 
or LDL phenotype B, characterized by a predominance of sdLDL particles (LDL diameter 
≤25.5 nm) [21]. Paraoxonase 1 (PON1) activity distribution on HDL subclasses was 
determined by the zymogram method according to Gugliucci et al. [16]. The areas under the 
peaks of densitometric scans of the sample represent the relative proportion of PON1 activity 
in particular HDL subclass, as previously described [17].  
 
Statistical analysis  
The data are shown as mean ± standard deviation for normally distributed variables or as 
median and interquartile range for non-normally distributed parameters. Differences among 
continuous variables were evaluated using Studentʹs t test for parametric data or Mann-
Whitney U test for non-parametric data. Since age differences between overweight/obese and 
normal weight PCOS patients were significant, ANCOVA and Quade’s tests (non-parametric 
ANCOVA) were applied for further analysing of parametric and non-parametric data, 
respectively, with age as a covariate. Spearman’s correlation analysis was performed to 
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subclasses and risk scores. To determine the Dyslipidemia score we standardised all the 
variables by calculating Z scores for LDL-C, TG and HDL-C using mean and standard 
deviation calculated from healthy population data from our laboratory. Thereafter, the 
Dyslipidemia score was calculated according to the equation: average of the standardised 
variables (LDL-C+TG)/2 minus standardised HDL-C. The OXY-score was calculated by 
subtracting the Protective score from the Damage score using the equation given by Veglia et 
al. [22]. The Protective score was calculated as an average of standardised antioxidant 
variables (TAS, SOD and PON1 activity) while the Damage score was calculated as an 
average of standardised prooxidant factors (AOPP, TOS, PAB and MDA). The Inflammation 
score was determined in both groups after standardisation of CRP as an acute phase protein. 
Dyslipidemia-Oxy-Inflammation (DOI) score was calculated as the sum of the Dyslipidemia 
score, OXY-score, and the Inflammation score. All variables with non-normal distributions 
were log-transformed before computation. To determine the predictors of LDL phenotype B 
in PCOS, univariate logistic regression analysis was performed. Dependent variable was LDL 
phenotype, risk group included PCOS patients with LDL B phenotype, while the patients 
with LDL A phenotype formed the reference group. As independent variables, age, BMI and 
those that were significantly different between the patients with LDL phenotypes A and B 
(TG, TAS, SOD and PON1 activity on HDL 2b, HDL 3b and HDL 3c subclasses) were 
tested. Multivariate logistic regression analysis (backward selection) was applied to 
predictors which in univariate analysis reached P value equal or less than 0.100 (TG, TAS, 
SOD and PON activity on HDL 2b, HDL 3b and HDL 3c subclasses) in order to determine 
the best model consisted of independent predictors of LDL phenotype B. Statistical analysis 
was performed using the Statistical Package for the Social Sciences (version 22, SPSS Inc. 
Chicago, USA). P value <0.05 was considered statistically significant for all analyses.  
 
Results 
The demographic, biochemical and lipoprotein subclasses distribution data in normal weight 
and overweight or obese PCOS patients are presented in Table 1. As expected, normal weight 
PCOS patients had significantly lower BMI, WC and WHR compared to overweight or obese 
PCOS patients. Overweight/obese PCOS patients were older than their normal weight 
counterparts. Fasting glucose concentration was similar in both groups, but the levels of CRP 
were significantly higher in overweight or obese PCOS patients. The levels of TC, TG and 
LDL-C were significantly higher, while HDL-C was significantly lower in overweight or 
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age. No significant differences were found in LDL particle size and subclasses distribution 
between the two groups of PCOS patients. On the other hand, overweight or obese PCOS 
women had significantly lower HDL particle diameters (P<0.05) and higher proportion of 
HDL 3a subclasses compared to normal weight PCOS patients (P<0.05), even after 
adjustment for age. 
The characteristics of OS status in both PCOS groups are shown in Figure 1. 
Significantly higher levels of prooxidant parameters (TOS and AOPP) were found in 
overweight or obese PCOS patients compared to normal weight PCOS patients. The observed 
differences between the two PCOS groups persisted after adjustment for age. We did not find 
significant differences in PON1 activity (Figure 1) and PON1 distribution on HDL subclasses 
(data not shown) between normal weight and overweight or obese PCOS groups.  
Table 2 shows the results of Spearmanʹs correlation analysis between lipoprotein data 
and parameters of OS status among all PCOS patients (overweight/obese and normal weight 
women). We found that the smaller LDL particle diameters were in correlation with higher 
levels of AOPP. Relative proportion of LDL I subclasses was positively associated with TAS 
and negatively with PAB. The proportion of small LDL IV subclasses was in positive 
correlation with PAB and in negative correlation with TAS. The level of PAB was in positive 
correlation with HDL 2b, while in negative correlation with the proportion of HDL 2a 
subclasses. A significant positive correlation was found between SOD activity and proportion 
of HDL 3b subclasses, as well as between concentration of MDA and proportion of HDL 3a 
subclasses. 
Serum PON1 activity was positively associated with relative proportion of PON1 
activity on HDL 2b (ρ=0.204, P<0.05) and HDL 2a (ρ=0.335, P<0.01), and negatively with 
the proportion on HDL 3a (ρ=-0.312, P<0.01) and HDL 3b (ρ=-0.332, P<0.01) subclasses. In 
addition, PON1 activity on HDL 3b particles positively correlated with TAS (ρ=0.226, 
P<0.05) and TOS (ρ = 0.207, P<0.05), and negatively with PAB (ρ=-0.296, P<0.01). PON1 
activity on HDL 3c particles was in positive correlation with TOS (ρ = 0.207, P<0.05).  
To gain further insight in the interactive role of OS, dyslipidemia and inflammation, 
risk scores were calculated. As shown in Figure 2, all the scores, except Protective score, 
were higher in overweigt or obese PCOS patients. Smaller LDL size was associated with 
higher Dyslipidemia (ρ=-0.223, P<0.05), Damage (ρ = -0.241, P<0.05) and OXY (ρ=-0.213, 
P<0.05) scores. An inverse association was found between HDL size and Dyslipidemia score 
(ρ=-0.201, P<0.05), as well as between PON1 activity on HDL 3 subclasses and Protective 
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Next, we assessed the impact of LDL phenotype on lipid, OS status and PON1 
activity distribution on HDL subclasses in PCOS (Table 3). LDL phenotype B patients 
showed higher TG concentration, but HDL-C concentrations and HDL size did not differ 
between the groups. The data also showed significantly higher levels of parameters of 
antioxidant protection (TAS and SOD) in LDL phenotype B group. PON1 activity on HDL 
2b subclasses was significantly higher, whereas PON1 activity on HDL 3b and HDL 3c 
subclasses was significantly lower in women with LDL phenotype B. Serum PON1 activity 
was not different between PCOS patients with LDL A and B phenotypes. 
The concentration of TG, activity of SOD in the serum and the proportion of PON1 
activity on HDL 3b particles were indicated as significant predictors of LDL phenotype B 
(Table 4). In the multivariate analysis, PON1 activity on HDL 3b particles remained 
significantly associated with LDL phenotype B (OR = 0.781, 95%CI: 0.614-0.993; P<0.048), 
the association of SOD activity was of borderline significance (OR = 1.024, 95%CI: 0.999-
1.43; P=0.059), while TG lost significance revealed in univariate analysis. 
 
Discussion 
Dyslipidemia is the most common metabolic abnormality in PCOS, although the type and the 
extent of the disorder varies [2], as a result of complex interactions between 
hyperandrogenism, IR, environmental (nutrition, physical activity) and genetic factors [23]
 
[24]. Previous studies have shown that obese women with PCOS may have reduced LDL 
particle size, due to the increased sdLDL particles [25]. In the study of Phelan et al. [4], both 
PCOS and BMI were associated with decreased LDL size and redistribution towards smaller, 
pro-aterogenic particles. They concluded that, despite the fact that exact mechanisms of 
changed lipoprotein metabolism in PCOS are not known, hyperandrogenemia and increased 
central obesity could be causal factors. We assume that excess of androgen early in life of 
normal weight PCOS patients might be the reason for the absence of a significant difference 
in LDL particle size and subclasses between our PCOS groups. It is known that many factors, 
including BMI, ethnic origin, complexity of the syndrome (anovulatory vs. ovulatory) and 
diet have an impact on LDL-C in PCOS patients. In line with previous studies, the same 
factors may also influence LDL particles distribution [21]. So far, only few studies dealt with 
HDL subclasses distribution in PCOS. In the current study, overweight or obese PCOS 
patients had significantly smaller HDL particle diameters and higher proportions of small 
HDL 3a subclasses compared to normal weight patients (Table 1).This finding is in 
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PCOS patients and other groups with higher CVD risk [26], suggesting that obesity is the 
major contributor for the observed changes in HDL subclasses profile in PCOS. 
The results of previous studies have shown that women with PCOS have elevated 
markers of OS, as well as that PCOS, independently of obesity, may trigger OS [8]. In our 
study, TOS, an aggregative index of plasma oxidant state, and AOPP, a marker of oxidant-
mediated protein damage and a potent pro-inflammatory mediator, were increased in 
overweight or obese PCOS patients (Figure 1). This agrees with the findings of Blair et al. 
which showed significant difference in TOS levels between PCOS patients with respect to 
BMI [27]. Our previous study showed that PCOS patients had lower PON1 activity compared 
to the control group [9]. In the current study, however, PON1 activity and PON1 distribution 
on HDL subclasses did not differ between normal weight and overweight or obese PCOS 
patients (Figure 1). These results suggest that disease itself affects serum PON1 activity and 
distribution on HDL subclasses, regardless of BMI, which should be confirmed in the future 
studies in order to improve our understanding of PON1 status in PCOS.  
The results of the presented study demonstrated significant interplay between markers 
of OS status and lipoprotein subclasses distributions in PCOS. The markers of enhanced OS 
(AOPP, PAB) were associated with sdLDL particles, which may indicate higher potential for 
their oxidative modifications. The levels of oxLDL are increased in PCOS patients and 
represent a reliable predictor of CVD, as has been confirmed in the study of Macut et al. [6]. 
The observed associations between the levels of PAB and relative proportions HDL 2 
particles suggests that OS might also play the role in alterations of HDL metabolism in 
PCOS. In fact, OS is able to inhibit lecithin-cholesterol acyltransferase (LCAT) activity and 
consequently to affect the maturation of HDL particles, leading to the accumulation of small 
HDL 3 subclasses [17]. Furthermore, free radicals can also modify HDL particles [28]. In 
support of this hypothesis, our data showed that higher proportions of HDL 3a subclasses 
were associated with increased MDA concentrations, which is consistent with previous 
results [21]. Yet, the question that still remains disputable is which HDL subclass provides 
the strongest cardiovascular protection. It has been suggested that larger HDL 2 particles 
have higher atheroprotective potential, because their levels are reduced in patients with CVD 
or higher in premenopausal women [29]. However, in vitro studies have demonstrated that 
smaller HDL 3 particles are more effective cholesterol acceptors and also have superior 
antioxidant properties than larger HDL 2 particles [30]. Another controversy is centred 
around the exact localization of PON1 on HDL subclasses. Previous studies have determined 
that PON1 activity is most commonly found on smaller HDL 3 particles [30]
.
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proteomic studies have confirmed these findings [31], supporting the concept that smaller 
HDL 3 particles have greater antioxidative potential. Recently, a hypothesis has been raised 
that the localization of PON1 changes during maturation of HDL particles. Hence, the inverse 
association between serum PON1 activity with the proportions of PON1 activity on HDL 3 
subclasses observed in this current study can be explained by the rapid transfer from smaller 
HDL 3 to larger HDL 2 particles [29]. Moreover, our analysis showed that the proportion of 
PON1 activity on HDL 3 subclasses was associated with OS biomarkers. This finding 
suggests that exacerbated OS in PCOS may affect HDL maturation that yields to the 
accumulation of PON1 on smaller HDL 3 subclasses. On the other hand, there is also a 
possibility that the observed associations reflect superior antioxidative properties of small 
HDL 3 particles in the pro-oxidative conditions, such as PCOS [9]. The observed inverse 
association between PON 1 activity on HDL 3 particles and Protective score, representing 
general antioxidative potential of plasma, may support this assumption.  
Further analysis showed increased TAS and SOD activity in PCOS patients with LDL 
B phenotype, whereas the indices of enhanced OS did not differ between the two LDL 
phenotype groups (Table 3). LDL B phenotype denotes increased prevalence of sdLDL 
particles, which are more susceptible to oxidative modifications [6]. A finding of increased 
levels of antioxidants in the patients with LDL phenotype B suggests upregulation of 
antioxidative defence mechanisms to prevent OS exacerbration in PCOS. Analysis of PON1 
distribution on HDL subclasses showed that women with LDL phenotype B had lower PON1 
activity on HDL 3 subclasses, but higher activity on HDL 2b particles than the patients with 
LDL A phenotype. This finding can be a sign of reduced antioxidant capacity of HDL 3 
particles in conditions associated with increased CVD risk [29], such is the preponderance of 
sdLDL particles. A potential relevance of the observed associations was further confirmed in 
logistic regression analysis (Table 4). As we expected, TG concentration was pointed out as 
an important predictor of LDL B phenotype, which is consistent with the fact that 
hypertriglyceridaemia is one of the features of ALP. Nevertheless, higher activity of SOD, as 
well as reduced proportion of PON1 activity on small HDL 3b particles remained 
significantly associated with LDL B phenotype in multivariate analysis. It is now well 
established that atherogenesis starts at young age and continues throughout life, especially in 
the presence of risk factors such as obesity, dyslipidemia, inflammation and elevated OS, that 
are commonly seen in PCOS. Therefore, the evaluation of novel cardiometabolic risk factors 
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various conditions that alter maturation and remodelling of HDL particles, provide additional 
information to guide preventive measures in order to attenuate atherosclerosis progression.   
 
Strengths and Limitations  
The current study represents a comprehensive evaluation of OS status and lipoprotein 
subclasses distributions and provides novel data on PON1 distribution on HDL subclasses in 
PCOS. The studies that investigate PON1 distribution on HDL subclasses might provide 
further insight into mechanisms responsible for HDL dysfunction in various diseases. This 
may be of particular importance in individuals with increased cardiometabolic risk, such as 
young women with PCOS. The cross-sectional design of our study represents the limitation 
because it does not allow us to demonstrate the causality of the observed relationships. Future 
prospective studies with larger number of patients would be needed to further expand our 
observations.   Also, considering that this is a cross-sectional study and not an interventional 
study, we analyzed two groups of patients on standard diet that were diagnosed based on 
Rotterdam criteria including only combination of clinical, hormonal and ultrasound indices. 
We believe that the impact of diet could be used in future investigations to show how dietary 
interventions influence inflammation, oxidative stress and dyslipidemia in patients during 
prolonged period of follow-up or on specific therapeutic regimens.  
 
Conclusion 
Our data showed that OS is associated with pro-atherogenic changes in lipoprotein subclasses 
profiles in patients with PCOS. Obesity in the PCOS favours redistribution of HDL 
subclasses toward smaller particles with a lower antioxidant potential, particularly in the 
presence of sdLDL particles. Taking all into account, our data provide additional evidence in 
favour of advanced lipid and OS testing for future management of CVD risk in PCOS 
patients. 
 
Acknowledgements   
 
Financial Support 
This work was supported by Grants 200110 and by Grants 451-03-9/2021-14/200161 from 










niversity Library Svetozar M
arkovic , on 06 O
ct 2021 at 10:45:28 , subject to the Cam
bridge Core term








Author contributions   
All authors listed have contributed sufficiently to the study to be included as authors. 
Iva M. Perovic Blagojevic- carrying out the study, analysing the data, interpreting the 
findings, writing the article 
Jelena Z. Vekic- analysing the data, interpreting the findings 
Djuro P. Macut- formulating the research question(s), designing the study 
Svetlana D. Ignjatovic- formulating the research question(s), designing the study 
Milica M. Miljkovic- Trailovic- carrying out the study 
Aleksandra R. Zeljkovic- analysing the data, interpreting the findings 
Vesna V. Spasojevic-Kalimanovska- formulating the research question(s), designing the 
study 
Ivana B. Bozic-Antic- carrying out the study, collecting the samples 
Jelica D. Bjekic-Macut- carrying out the study, collecting the samples 
Biljana A. Kastratovic-Kotlica- carrying out the study, collecting the samples 
Zoran G. Andric- carrying out the study, collecting the samples 
Dusan S. Ilic- carrying out the study, collecting the samples  
Jelena M. Kotur-Stevuljevic- formulating the research question(s), designing the study 
 
Compliance with ethical standards 
 












niversity Library Svetozar M
arkovic , on 06 O
ct 2021 at 10:45:28 , subject to the Cam
bridge Core term












Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina 
GG et al, A survey of the polyctystic ovary syndrome in the Greek Island of Lesbos: 




Macut D, Bjekić-Macut J, Savić-Radojević A, Dyslipidemia and oxidative stress in 
PCOS. Front Horm Res, 2013;40:51-63. https://doi: 10.1159/000341683.  
[
3]  
Repaci A, Gambineri A, Pasquali R, The role of low-grade inflammation in the 




Phelan N, OʹConnor A, Kyaw-Tun T, Correia N, Boran G, Roche HM, Gibney J, 
Lipoprotein subclass patterns in women with polycystic ovary syndrome (PCOS) 
compared with equally insulin-resistant women without PCOS. J Clin Endocrinol Metab 
2010;95:3933-3939. https://doi: 10.1210/jc.2009-2444.  
[
5]  
Rizzo M, Berneis K, Lipid triad or atherogenic lipoprotein phenotype: a role in 




Macut D, Damjanovic S, Panidis D, et al, Oxidised low-density lipoprotein 
concentration - early marker of an altered lipid metabolism in young women with PCOS. 
Eur J Endocrinol 2006;155:131-136. https://doi: 10.1530/eje.1.02187.  
[
7]  
Gonzalez F, Rote NS, Minium J, et al, Reactive oxygen species-induced oxidative 
stress in the development of insulin resistance and hyperandrogenism in polycystic ovary 
syndrome. J Clin Endocrinol Metab 2006;91:336-340. https://doi: 10.1210/jc.2005-1696.  
[
8]  
Murri M, Luque-Ramirez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF, 
Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a 




Perovic Blagojevic I, Ignjatovic S, Macut D, Kotur-Stevuljevic J, Bozic-Antic I, 
Vekic J et al., Evaluation of a summary score for dyslipidemia, oxidative stress and 
inflammation (the DOI score) in women with polycystic ovary syndrome and its 









niversity Library Svetozar M
arkovic , on 06 O
ct 2021 at 10:45:28 , subject to the Cam
bridge Core term











Blanche PJ, Gon EL, Forte TM, Nichols AV, Characterization of human high 
density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 
1981;665:408-419. https://doi: 10.1016/0005-2760(81)90253-8.  
[
11]  
Mueller O, Chang E, Deng D, Franz T, Jing D, Kincaid R, Konigshofer Y, et al, 
PROCAM study: risk prediction for myocardial infarction using microfluidic high-
density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin 
Chem Lab Med 2008;46:490-498. https://doi: 10.1515/CCLM.2008.117.  
[
12]  
Mackness M, Mackness B, Targeting paraoxonase-1 in atherosclerosis. Expert Opin 
Ther Targets 2013;17:829-837. https://doi: 10.1517/14728222.2013.790367.  
[
13]  
Vekic J, Kotur-Stevuljević J, Jelić-Ivanović Z, Spasić S, Spasojević-Kalimanovska 
V, Topić A, Zeljković A, Stefanović A, Žunić G, Association of oxidative stress and 
PON1 with LDL and HDL particle size in middle-aged subjects. Eur J Clin Investig 
2007;37:715-723. https://doi: 10.1111/j.1365-2362.2007.01849.x.  
[
14]  
Aviram M, Vaya J, Paraoxonase 1 activities, regulation, and interactions with 




Rozenberg O, Aviram M, S-Glutathionylation regulates HDL-associated 
paraoxonase 1 (PON1) activity. Biochem Biophys Res Commun 2006;351:492-498. 
https://doi: 10.1016/j.bbrc.2006.10.059.  
[
16]  
Gugliucci A, Caccavello R, Kotani K, Sakane N, Kimura S, Enzymatic assessment 
of paraoxonase 1 activity on HDL subclasses: a practical zymogram method to assess 




Miljkovic M, Stefanovic A, Vekic J, Zeljkovic A, Gojkovic T, Simic-Ogrizovic S, 
Bogavac-Stanojevic N, Cerne D, Ilic J, Stefanovic I, Jelic-Ivanovic Z, Spasojevic-
Kalimanovska V, Kotur-Stevuljevic J, Activity of paraoxonase 1 (PON1) on HDL 2 and 




Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group, Revised 
2003 consensus on diagnostic criteria and long-term health risks related to polycystic 









niversity Library Svetozar M
arkovic , on 06 O
ct 2021 at 10:45:28 , subject to the Cam
bridge Core term











Warnick GR, Knopp RH, Fitzpatrick V, Branson L, Estimating low-density 
lipoprotein cholesterol by the Friedewald equation is adequate for classifying patients on 
the basis of nationally recommended cutpoints. Clin Chem 1990;36:15-19.  
[
20]  
Rainwater DL, Moore PH, Gamboa IO, Improved method for making 
nondenaturing composite gradient gels for the electrophoretic separation of lipoproteins. 
J Lipid Res 2004;45:773-775. https://doi: 10.1194/jlr.D300035-JLR200.  
[
21]  
Vekic J, Topic A, Zeljkovic A, Jelic-Ivanovic Z, Spasojevic-Kalimanovska V, LDL 
and HDL subclasses and their relationship with Framingham risk score in middle-aged 




Veglia F, Cighetti G, De Franceschi M, Zingaro L, Boccotti L, Tremoli E et al, 
Age- and gender-related oxidative status determined in healthy subjects by means of 
OXY-SCORE, a potential new comprehensive index. Biomarkers 2006;11:562-73..  
[
23]  
Başar Gökcen B, Akdevelioğlu Y, Canan S, Bozkurt N, : Evaluation of the 




Pala L, Barbaro V, Dicembrini I, Rotella CM, The therapy of insulin resistance in 




Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinas GA, 
Carmina E, Atherogenic forms of dyslipidemia in women with polycystic ovary 




Kim JY, Tfayli H, Michaliszyn SF, Lee S, Arslanian S, Distinguishing 
characteristics of metabolically healthy versus metabolically unhealthy obese adolescent 




Blair SA, Kyaw-Tun T, Young IS, Phelan NA, Gibney J, McEneny J., Oxidative 
stress and inflammation in lean and obese subjects with polycystic ovary syndrome. J 
Reprod Med. 2013;58:107-114.  









niversity Library Svetozar M
arkovic , on 06 O
ct 2021 at 10:45:28 , subject to the Cam
bridge Core term








28]  Gojkovic T, Joksic J, Sopic M, Gulan B, Janac J, Milosevic S, Oxidative stress and 
paraoxonase 1 status in acute ischemic stroke patients. Atherosclerosis 2015;241:192-
198. https://doi: 10.1016/j.atherosclerosis.2015.05.016 .  
[
29]  
Gugliucci A, Menini T, Paraoxonase 1 and HDL maturation. Clin Chim Acta 
2015;439:5-13. https://doi: 10.1016/j.cca.2014.09.016.  
[
30]  
Camont L, Lhomme M, Rached F, Le Goff W, Negre-Salvayre A, Salvayre R, et al. 
Small, dense high-density, lipoprotein-3 particles are enriched in negatively charged 
phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, 
anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 
2013;33:2715-2723. https://doi: 10.1161/ATVBAHA.113.301468.  
[
31]  
Heinecke JW, The HDL, proteome: a marker - and perhaps mediator - of coronary 












niversity Library Svetozar M
arkovic , on 06 O
ct 2021 at 10:45:28 , subject to the Cam
bridge Core term








Table 1 Demographic, biochemical data and lipoprotein subclasses distribution in PCOS 
subgroups 
 PCOS  
 
 
Parameter Normal weight Overweight or obese 
 
P 
N 60 55  
Age, years 25.4 ± 4.9 27.3 ± 5.2 <0.05 
BMI, kg/m
2















Glucose, mmol/L 4.87 ± 1.39 5.02 ± 0.46 0.443 
CRP, mg/L 
#
 0.75 (0.50-1.35) 3.50 (1.80-6.10) <0.001 

















 0.71 (0.62-0.91) 1.32 (0.86-2.19) <0.001 
LDL size, nm 
27.00 ± 1.34 26.63 ± 1.28 0.131 
LDL I, % 
21.2 ± 3.1 21.6 ± 3.3 0.526 
LDL II, % 
25.2 ± 4.2 25.8 ± 4.4 0.456 
LDL III, % 
21.1 ± 2.7 20.5 ± 3.0 0.307 
LDL IV, % 
32.5 ± 5.1 32.1 ± 5.9 0.678 
sdLDL, % 
53.6 ± 5.5 52.7 ± 6.6 0.388 
HDL size, nm 
10.62 ± 0.79 10.24 ± 0.91 <0.05 
HDL 2b, % 
52.8 ± 10.6 50.3 ± 9.3 0.192 
HDL 2a, % 20.9 ± 7.6 21.4 ± 4.3 0.705 
HDL 3a, % 
11.5 ± 3.3 13.1 ± 4.2 <0.05 
HDL 3b, % 
6.3 ± 3.2 6.5 ± 3.2 0.749 
HDL 3c, % 
8.5 ± 4.6 8.5 ± 3.6 0.966 
Data are presented as mean ± standard deviation and compared by Studentʹst test. 
# Data are presented as median (interquartile range) and compared by Mann-Whitney U test. 
BMI -Body Mass Index, CRP-C Reactive Protein, HDL-C –High-Density Lipoprotein Cholesterol, 
LDL-C –Low-Density Lipoprotein Cholesterol, TG -Triglycerides, LDL- Low-density Lipoprotein, 
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LDL size, nm -0.058 -0.214
* 
-0.180 -0.111 0.121 -0.132 -0.023 




 -0.048 -0.039 
LDL II, % -0.019 -0.037 -0.073 -0.154 0.158 -0.063 0.030 
LDL III, % -0.068 0.002 -0.072 0.175 -0.090 0.068 0.092 




 0.055 -0.001 
HDL size, nm 0.011 -0.126 0.080 0.050 0.001 0.033 0.075 
HDL 2b, % -0.058 -0.131 -0.087 0.201
*
 -0.062 -0.090 0.006 
HDL 2a, % 0.047 0.050 -0.160 -0.369
***
 0.169 -0.160 -0.042 
HDL 3a, % 0.045 0.136 0.225
*
 -0.169 0.077 0.055 -0.089 
HDL 3b, % 0.020 0.112 0.023 0.026 -0.139 0.187
*
 0.001 
HDL 3c, % -0.001 0.082 0.074 -0.006 -0.040 0.166 0.022 







TOS- Total Oxidant Status, AOPP- Advanced Oxidation Protein Products, MDA-
Malondialdehyde, PAB- Pro-Oxidant Antioxidant Balance, TAS- Total Antioxidant Status, 
SOD- Superoxide Dismutase, PON1- Paraoxonase-1, LDL- Low-density Lipoprotein, HDL- 
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Table 3 Lipid status, oxidative stress status and PON1 activity distribution on HDL 
subclasses in PCOS patients according to LDL phenotype 
Parameter LDL phenotype B LDL phenotype A P 
N 15 100  
BMI, kg/m
2




















 1.32 (0.90-2.31) 0.83 (0.66-1.37) <0.05 







 37.7 (30.0-47.4) 37.7 (30.0-48.7) 0.801 
AOPP, μmol/L 
#
 38.9 (27.4-74.3) 30.7 (23.2-48.8) 0.146 
MDA, μmol/L 
#
 4.0 (3.3-5.9) 3.5 (2.7-4.5) 0.209 
PAB, U/L 
#
 102.5 (66.0-138.51) 79.0 (48.0-105.5) 0.207 
TAS, μmol/L 
#
 1085.0 (902.0-1244.5) 935.0 (716.5-1077.5) <0.05 
SOD, U/L 
#
 138.5 (114.5-158.5) 118.0 (105.0-139.5) <0.05 
PON1, U/L 
#
 287.5 (212.5-600.5) 230.0 (163.5-479.0) 0.177 
PON1 HDL 2b, % 56.2 ± 11.4 50.9 ± 2.4 <0.001 
PON1 HDL 2a, % 24.9 ± 4.3 24.0 ± 5.9 0.565 
PON1 HDL 3a, % 10.6 ± 2.9 12.0 ± 5.4 0.357 
PON1 HDL 3b,% 4.6 ± 2.8 6.6 ± 3.2 <0.05 
PON1 HDL 3c, % 3.7 ± 2.5 6.5 ± 5.2 <0.01 
#
 Data are presented as median (interquartile range) and compared by Mann-Whitney U test. 
BMI- Body Mass Index, HDL-C- High Density Lipoprotein Cholesterol, LDL-C- Low-
density Lipoprotein Cholesterol, TG- Triglycerides, HDL- High Density Lipoprotein, TOS-
Total Oxidant Status, AOPP- Advanced Oxidation Protein Products, MDA- 
Malondialdehyde, PAB- Pro-Oxidant Antioxidant Balance, TAS- Total Antioxidant Status, 
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Table 4 Univariate logistic regression analysis of LDL phenotype B predictors in PCOS  
Parameter OR (95% CI) P 
Age, years 1.067 (0.959-1.188) 0.234 
BMI, kg/m
2
 1.014 (0.937-1.099) 0.725 
TG, mmol/L 2.152 (1.144-4.046) <0.05 
TAS, μmol/L 0.998 (0.997-1.000) 0.085 
SOD, U/L 1.024 (1.004-1.044) <0.05 
PON1 HDL 2b, % 1.051 (0.992-1.114) 0.092 
PON1 HDL 3b,% 0.795 (0.646-0.975) <0.05 
PON1 HDL 3c, % 0.852 (0.723-1.003) 0.055 
BMI- Body Mass Index, TG- Triglycerides, TAS- Total Antioxidant Status, SOD- 
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Fig. 1 Oxidative stress status in normal weight and overweight or obese PCOS patients. The 
box’s horizontal edges (lower and upper) indicate the 25th and 75th percentiles, respectively 
and the horizontal line through the box indicates the median value. Horizontal lines at the 
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Fig. 2 The scores of oxidative stress, dyslipidemia and inflammation in normal weight and 
overweight or obese PCOS patients. The box’s horizontal edges (lower and upper) indicate 
the 25th and 75th percentiles, respectively and the horizontal line through the box indicates 
the median value. Horizontal lines at the lower and upper whiskers indicate minimum and 
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